

FMC63 scFv, His Tag (MALS verified)

Catalog # CD9-M52Hb



Source

FMC63 scFv, His Tag (CD9-M52Hb) is expressed from human 293 cells (HEK293). It mimics the scFv presented on CAR-T cells which target CD19.

Specificity

Specifically recognizes the antigen-recognition domain of CD19-derived CARs.

Purity

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

Endotoxin

Less than 1.0 EU per μg by the LAL method.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.


SDS-PAGE



FMC63 scFv, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-Elisa

SEC-MALS



The purity of FMC63 scFv, His Tag (Cat. No. CD9-M52Hb) is more than 90% and the molecular weight of this protein is around 25-37 kDa verified by SEC-MALS.

[Report](#)

Discounts, Gifts,
and more!




FMC63 scFv, His Tag (MALS verified)

Catalog # CD9-M52Hb



BIOSYSTEMS
Acro



Immobilized Human CD19 (20-291), Fc Tag, premium grade (Cat. No. CD9-H5251) at 2 µg/mL (100 µL/well) can bind FMC63 scFv, His Tag (Cat. No. CD9-M52Hb) with a linear range of 4-31 ng/mL (QC tested).

Background

FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. So far, most of reported CART19 trials contain the anti-CD19 scFv derived from FMC63, including the two FDA-approved CARs Kymriah and Yescarta.

Clinical and Translational Updates

Discounts, Gifts,
and more!



➤ www.acrobiosystems.com

3/27/2024